HR Execs on the Move

Acreage Holdings

www.acreageholdings.com

 
Headquartered in New York City, Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company`s national retail store ‎brand, The Botanist. Acreage`s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Clemildo Senger
 Vice President Finance Profile
Katrina Yolen
 Chief Marketing Officer Profile

Similar Companies

Jubilant Pharma

Follow us for career advice, news & jobs. Find your Formula for Success at Jubilant Pharma! Subsidiaries: HollisterStier, Cadista, Radiopharma, and JGL.

Sol-Millennium Medical Group

SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...

Warner Chilcott

Warner Chilcott is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Zynex Medical

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring.

Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.